Greenwich LifeSciences to Resume Stock Repurchase Program

Author's Avatar
May 23, 2022

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced today it would resume its existing Stock Repurchase Program.